Pemigatinib (Pemazyre)

Canada’s Drug Agency (CDA-AMC) recommends that Pemazyre be reimbursed by public drug plans for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with an FGFR2 fusion or other rearrangement if certain conditions are met. Pemazyre should only be covered to treat adult patients with advanced, metastatic, or surgically unresectable CCA confirmed by histology or cytology, have FGFR2 abnormalities (fusions or other rearrangements), have received at least 1 prior systemic therapy, and are in relatively good health (as measured by performance status). Pemazyre should only be reimbursed if prescribed by clinicians with expertise in managing patients with gastrointestinal malignancies and if the cost of Pemazyre is reduced.